secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2026-11-10T21:22:49+00:00
Accession:  0001357459-26-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Palisade Bio Q3 net loss widens to $14.6M; ASCENTRA-UC dosing underway, topline set for Q4 2027
--------------------------------------------------------------------------------

- Net loss $14.6M ($0.07/share) vs $2.9M ($0.38/share) in Q3 2025; R&D rose to $10.6M from $1.4M and G&A to $5.1M from $1.5M on PALI-2108 Phase 2 costs.
- Cash and equivalents of $113.6M at September 30, 2026; company says this funds operations through the ASCENTRA-UC (Q4 2027) and ASCENTRA-CD (Q1 2028) efficacy readouts.
- First patient dosed in Phase 2b ASCENTRA-UC on October 27, 2026; 29 of 30 U.S. sites activated, ~115 sites planned globally, ~204 patients, 15 mg and 30 mg vs placebo.
- FDA cleared the Crohn's disease IND on September 22, 2026; Phase 2a ASCENTRA-CD (~60 patients, 30 mg once daily) enrollment targeted Q1 2027, primary readout Q1 2028.
- Presented five posters at ACG 2026 and one oral plus three moderated posters at UEG Week 2026, including endoscopic improvement within two weeks in five fibrostenotic Crohn's patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/0001357459-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/pali-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001357459-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer